Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Bellerophon reports initial data from acute hemodynamic study of INOpulse

Nov. 13, 2019

Cerecor announces milestones in clinical development programs of CERC-301 and CERC-802

Nov. 12, 2019

Terns patents new MAP3K5 inhibitors

Nov. 5, 2019

Positive interim safety and efficacy data presented for OTS Allocetra

Nov. 5, 2019

Gene therapy can treat, prevent heart failure

Nov. 5, 2019

Cyclerion Therapeutics presents topline data from two phase II studies of praliciguat

Oct. 31, 2019

Hypothermia activates hypoxia protein, benefits metabolism

Oct. 30, 2019

MyoKardia announces promising results from phase IIa study of MYK-491

Oct. 29, 2019

Flavonoid baicalin upregulates miR-126-5p: a potential therapeutic strategy against atherosclerosis

Oct. 25, 2019

FDA approves Farxiga to reduce risk of hospitalization for heart failure in type 2 diabetes patients

Oct. 21, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...